US FDA approves CombinatoRx/Covidien's extended-release Exalgo for pain
This article was originally published in Scrip
Executive Summary
The US FDA has approved CombinatoRx/Covidien's Exalgo (extended-release hydromorphone) for the management of moderate to severe pain in opioid-tolerant patients who need around-the-clock analgesia.